Study at a glance
How was vitamin D tested for inflammation in adults with low levels?
A trial randomly assigned 65 adults with low vitamin D levels and overweight or obesity to vitamin D or a placebo, a treatment without vitamin D. Researchers measured blood signs of inflammation and a signalling process in immune cells over 16 weeks. The main reported analysis included 54 people who completed the required study steps.
Did raising vitamin D levels improve signs of inflammation?
Vitamin D blood levels rose substantially in the supplement group, from about 31 to 88 nmol/L. The trial did not find a clear improvement in the measured signs of inflammation compared with placebo. One immune-cell signalling measurement fell in both groups. A fall within the vitamin D group alone therefore did not demonstrate a supplement effect.
Did the longer VITAL trial show lasting changes in inflammation?
A separate analysis from the VITAL trial followed a different, older population, most of whom did not start with low vitamin D. One blood marker of inflammation was lower with vitamin D at two years, but that difference did not persist at four years. Other measured inflammatory substances did not show a consistent beneficial pattern. This does not establish a lasting, general reduction in inflammation.
Do these studies establish a treatment for inflammation?
The 16-week trial was small, and inflammation was not its main outcome. Some substances were too low for the tests to measure reliably. The findings do not rule out every possible effect, but they also do not establish a subgroup that clearly benefited. Raising vitamin D levels and improving inflammation are different outcomes. Neither study establishes an anti-inflammatory dose, a target blood level or fewer inflammatory symptoms or disease events.
Read the full article below ↓In a small randomised trial of adults with low vitamin D concentrations and overweight or obesity, supplementation substantially increased circulating 25-hydroxyvitamin D but did not produce a clear improvement in the measured inflammatory outcomes over 16 weeks. The study is useful because it directly tested a deficient population. Its findings also show why correcting a blood measurement and demonstrating an anti-inflammatory effect are separate questions. Read the companion Vitamin D Supplementation and Low-Grade Inflammation in Deficient Adults: Study Summary.
The question behind the trial
In this double-blind, placebo-controlled trial, Mousa and colleagues investigated whether vitamin D supplementation would change inflammatory markers and NF-κB activity in adults whose baseline 25-hydroxyvitamin D concentration was no more than 50 nmol/L. Participants were aged 18 to 60 years and had a body mass index of at least 25 kg/m². The paper therefore addressed a defined population rather than an unselected sample with predominantly adequate vitamin D status.
The study belongs within Vitamin D and Chronic Inflammation, but it did not measure every component of chronic inflammation. It examined selected circulating markers and a cellular signalling measurement over a relatively short intervention. Persistent tissue inflammation, inflammatory symptoms, disease events and long-term immune function were not interchangeable with those outcomes.
There is a straightforward reason this design matters. An association between a low vitamin D concentration and a higher inflammatory marker cannot establish which caused which, or whether another characteristic contributed to both. Random allocation to supplementation or placebo can test whether changing exposure changes the outcome under the conditions of the trial. It answers a more specific causal question than a cross-sectional association.
How the trial was organised
Sixty-five participants were randomised: 33 to vitamin D and 32 to placebo. The reported per-protocol analysis included 54 participants, with 28 in the vitamin D group and 26 in the placebo group. The difference between randomised and analysed numbers matters because the final comparison did not contain everyone originally allocated.
The intervention used a loading dose of 100,000 IU followed by 4,000 IU daily for 16 weeks. These amounts are details of a supervised research protocol, not recommendations for personal use. A trial regimen cannot be converted into a general prescription from this paper, particularly when its inflammatory results did not establish benefit.
The investigators measured circulating 25-hydroxyvitamin D to determine whether the intervention changed vitamin D status. They also assessed high-sensitivity C-reactive protein and several cytokines, alongside NF-κB activity in peripheral blood mononuclear cells. Those cells are a mixture of circulating immune-cell populations, not a direct sample of every inflamed tissue.
The distinction between the blood-status measurement and the biological outcomes is central to Vitamin D Status vs Vitamin D Effect. A rise in 25-hydroxyvitamin D confirms that the intervention changed the measured exposure marker. It does not, by itself, show that inflammation improved. The trial was designed to observe both, so the two results can be considered separately.
Vitamin D status increased substantially
Mean 25-hydroxyvitamin D increased from approximately 31.4 to 88.4 nmol/L in the intervention group. In the placebo group it changed from approximately 34.2 to 36.1 nmol/L. The groups therefore differed clearly in their change in vitamin D status over the study period.
This finding helps narrow the interpretation of the inflammatory results. The absence of a clear anti-inflammatory effect cannot simply be attributed to the supplementation having failed to raise the measured vitamin D concentration. The biological intervention produced a substantial status change, yet the selected downstream outcomes did not show a corresponding persuasive between-group improvement.
It does not follow that 88.4 nmol/L is an optimal target, or that a higher concentration would necessarily have changed the result. The trial did not compare multiple achieved targets to determine an optimum. The reported concentration describes the group’s response to this protocol and should remain a descriptive result.
The inflammatory-marker comparison
High-sensitivity C-reactive protein did not show a statistically clear advantage for vitamin D. The reported changes were about −0.1 mg/L in the intervention group and −0.4 mg/L in the placebo group, with a between-group P value of 0.9. The direction and size of these changes do not support presenting this trial as evidence that supplementation lowered this marker.
NF-κB activity also declined in both groups. The reported mean changes were approximately −17.8 and −13.2 pg/µg protein in the vitamin D and placebo groups, respectively. The between-group comparison was not significant. A reduction within the supplemented group is not sufficient to demonstrate an intervention effect when a similar reduction occurs in the comparison group.
This point is particularly important for Vitamin D and Inflammatory Signalling. A mechanistic expectation that vitamin D can influence NF-κB does not determine the result of a human trial. The human measurement must be judged on its own allocation, sampling, assay and comparison. Cellular experiments can motivate the hypothesis without guaranteeing that the hypothesis will be supported clinically.
The cytokine findings did not provide a coherent alternative pattern of benefit. Some measured analytes, including IL-17 and interferon-γ, were undetectable in many samples. When an assay cannot quantify an analyte in much of the sample, the correct conclusion is limited measurement information. It is not proof that the cytokine was biologically absent or that the groups were equivalent.
Why within-group changes are not enough
A before-and-after change can arise for many reasons besides the assigned supplement. Measurements fluctuate, participants may change behaviours, and initially unusual values can move closer to their typical range on repeat testing. The placebo group helps estimate changes that occurred without the active intervention.
For the intervention question, the important comparison is therefore the difference in change between groups, with the analysis appropriate to the trial. Selecting a nominally significant change only in the vitamin D group would answer a different question and risk exaggerating the evidence. Here, the main between-group inflammatory results did not show a convincing benefit.
The paper also involved several outcomes and comparisons. Testing many possibilities increases the chance that at least one apparently positive result will occur by chance. A nominal P value near 0.05 should not be treated as a secure discovery when the relevant multiple-comparison threshold is more stringent. The authors’ analysis and the pattern across outcomes must be considered together.
Subgroup analyses did not establish a reliable responsive subgroup. Splitting an already small trial further reduces precision. It also creates more opportunities for unstable estimates. The results do not justify identifying a particular deficient subgroup for an anti-inflammatory treatment claim on the basis of this study.
What a null result can and cannot establish
The trial did not demonstrate a clear reduction in its inflammatory outcomes. That is a meaningful finding, especially because vitamin D status rose substantially. It challenges the assumption that a deficient population must show measurable anti-inflammatory benefit whenever its vitamin D concentration is increased.
However, failure to detect a difference is not the same as proving that every clinically meaningful effect is absent. The inflammatory outcomes were secondary, and the study was not designed as a definitive equivalence trial for them. The sample was small and the intervention lasted 16 weeks. Precision, outcome variability and the size of an effect that could reasonably be detected all constrain interpretation.
The population boundary is equally important. These were adults with overweight or obesity and low vitamin D concentrations. The result does not automatically apply to children, frail older adults, people with a specific inflammatory disease, or all possible supplementation regimens. Conversely, those possible differences do not provide evidence that supplementation would work in another group; they identify unanswered questions.
The biological boundary also matters. A blood marker can be unchanged while an unmeasured local process changes, or vice versa. This study did not test every tissue compartment. It would therefore be too broad to claim that vitamin D has no effect on inflammation anywhere in the body. The defensible statement concerns the outcomes, participants and duration actually studied.
How a longer trial qualifies the picture
Dong and colleagues’ VITAL biomarker analysis provides a useful longer-duration comparison, although it studied a different population and does not replace the Mousa trial. In the VITAL analysis, 1,054 participants contributed to the biomarker study at baseline. Participants were older on average, and most were not vitamin D deficient by the study’s reported threshold.
The vitamin D assignment was 2,000 IU daily within a factorial trial that also tested omega-3 supplementation. Again, this is a description of research exposure, not a dosing recommendation. Blood markers were evaluated at two and four years, making the analysis informative about whether an observed marker change was sustained.
High-sensitivity C-reactive protein was lower with vitamin D at two years in the reported analysis, but this finding did not persist at four years. IL-6, IL-10 and TNF-related measurements did not show a consistent beneficial pattern. The longer study therefore adds a time-dependent qualification rather than a simple confirmation of broad inflammatory suppression.
The VITAL population’s baseline status, age and follow-up differ from the Mousa population. These differences prevent treating the two studies as identical tests. They also prevent concluding that one study invalidates the other. Taken together, they show that the effect on an inflammatory biomarker can depend on the population, endpoint and time point, and that a positive result need not be sustained.
What remains unproven about chronic inflammation
Neither trial establishes that supplementation prevents persistent excessive immune activation, the broader topic discussed in Vitamin D and Immune Overactivation. Neither demonstrates that changes in a blood marker translate into fewer inflammatory symptoms or disease events through the proposed pathway. A biomarker result can be scientifically informative without establishing a clinical benefit.
The Mousa trial also does not answer whether vitamin D slows the decline in immune function discussed in Vitamin D and Immune Ageing. Its duration and outcomes were not designed to assess ageing of immune function. It would be inappropriate to extend a 16-week signalling comparison into a claim about long-term immune rejuvenation, even if the short-term result had been positive.
Similarly, Vitamin D and Oxidative Stress is an adjacent physiological topic rather than a mechanism established by this trial. The inflammatory outcomes do not show that a redox change mediated the response. Adding an unmeasured mechanism would make the explanation sound more complete while moving beyond the evidence.
The broader lesson is reflected in Why Vitamin D Results Differ: studies with different participants, starting concentrations, durations and outcome definitions should not be collapsed into a single “works” or “does not work” verdict. A careful interpretation specifies what changed, what did not, and which questions were not tested.
Appraisal of the evidence
The principal strength is randomisation in a deliberately low-status population, combined with measurement of both the vitamin D response and downstream inflammatory outcomes. The substantial separation in achieved status makes the absence of a corresponding inflammatory signal especially relevant to the study question.
The principal limitations are the small analysed sample, the per-protocol analysis, the secondary nature of the inflammatory outcomes, multiple comparisons and measurement limitations for some cytokines. These features reduce the certainty with which small effects or subgroup differences can be excluded. They do not justify converting the result into a positive finding.
The appraisal here is an interpretation of the reported methods and results, distinct from any broader claim about vitamin D’s roles in health. The study addresses an anti-inflammatory hypothesis under particular conditions. It does not settle every reason for assessing or treating vitamin D deficiency, nor does it provide individual treatment advice.
Conclusion
In this randomised trial, vitamin D supplementation raised 25-hydroxyvitamin D substantially but did not clearly improve the measured inflammatory markers or NF-κB activity over 16 weeks. The result supports a separation between correcting a low status measurement and demonstrating an anti-inflammatory effect.
The longer VITAL biomarker analysis adds a limited, time-dependent hs-CRP finding rather than evidence of sustained broad cytokine suppression. Together, the studies support cautious, outcome-specific interpretation. They do not establish an anti-inflammatory dose, a universal target concentration or a clinical benefit mediated by reduced chronic inflammation.
This page is an original Vitamin D3 For Life explanation and critical appraisal of the research cited below.
Primary source and publication details
Related reading
Association of a Combination of Sarcopenia and Type 2 Diabetes with Blood Parameters, Nutrient Intake, and Physical Activity: A Nationwide Population-Based Study
This study aimed to investigate the association of sarcopenia and type 2 diabetes (T2D) with blood parameters, nutrient intake, and physical activity in older Korean adults.
Original paper ↗Read more →Associations between the TyG index and the ɑ-Klotho protein in middle-aged and older population relevant to diabetes mellitus in NHANES 2007 to 2016
With this in mind, our study aimed to investigate the relationship between the TyG index and soluble α-Klotho protein levels in US populations, both with and without diabetes mellitus.
Original paper ↗Read more →Does inflammation moderate the effect of vitamin D supplementation on depressive symptoms? Results of an interventional study in children and adolescents
These analyses aimed to determine whether treatment effects on depressive symptoms significantly differed depending on baseline CRP levels.
Original paper ↗Read more →The relationship between hematological indices as indicators of inflammation and 25-hydroxyvitamin D3 status in newborns
The aim of the study is to evaluate the relationship between 25(OH)D3 (vitamin D) status and new defined systemic inflammatory markers neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), and platelet to lymphocyte ratio (PLR) in newborns.
Original paper ↗Read more →Vitamin D as a Modifiable Risk Factor for Juvenile Idiopathic Arthritis: A Systematic Review and Meta-analysis of Observational Studies Comparing Baseline Vitamin D in Children with JIA to Individuals Without
The aim was to elucidate potential therapeutic implications of vitamin D in the management of JIA.
Original paper ↗Read more →Vitamin D status & associations with inflammation in older adults
We aimed to investigate the association of C-reactive protein (CRP) with vitamin D status in a representative sample of the older Irish population.
Original paper ↗Read more →Vitamin D Supplementation for Premenstrual Syndrome-Related inflammation and antioxidant markers in students with vitamin D deficient: a randomized clinical trial
This randomized clinical trial study was undertaken to investigate the effect of vitamin D supplementation on inflammatory and antioxidant markers in 44 vitamin D deficient (25(OH)D.
Original paper ↗Read more →Effect of vitamin D supplementation on inflammation and nuclear factor kappa-B activity in overweight/obese adults: a randomized placebo-controlled trial
Yet, no trials have examined the effects of vitamin D supplementation on NFκB activity in-vivo in humans.
Original paper ↗Read more →Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial
Background: The VITAL study was a nationwide, randomized, double-blind, placebo-controlled, 2 × 2 factorial trial of vitamin D3 (2000 IU/day) and marine n-3 FAs (1 g/day) supplements.
Original paper ↗Read more →Effect of low energy diet for eight weeks to adults with overweight or obesity on folate, retinol, vitamin B12, D and E status and the degree of inflammation: a post hoc analysis of a randomized intervention trial
The purpose of this study was to investigate the effect of weight loss on folate, retinol, vitamin B12, D and E status and the degree of inflammation.
Original paper ↗Read more →Does inflammation moderate the effect of vitamin D supplementation on depressive symptoms? Results of an interventional study in children and adolescents
In the first randomized controlled trial (RCT) in depressed, vitamin D-deficient adolescents (DRKS00009758), symptom reduction emerged in only one of three outcomes.
Original paper ↗Read more →Anti-Inflammatory Effects of Vitamin D on Human Immune Cells in the Context of Bacterial Infection
Vitamin D induces a diverse range of biological effects, including important functions in bone health, calcium homeostasis and, more recently, on immune function.
Original paper ↗Read more →Association between circulating ascorbic acid, α-tocopherol, 25-hydroxyvitamin D, and plasma cytokine concentrations in young adults: a cross-sectional study
Our objective was to examine the association between circulating concentrations of ascorbic acid, α-tocopherol, and 25(OH) D and a panel of pro-inflammatory cytokines in an ethnically diverse population of young adults.
Original paper ↗Read more →Phase Angle: A Possible Biomarker to Quantify Inflammation in Subjects with Obesity and 25(OH)D Deficiency
Considering the lack of evidence correlating the 25(OH)D levels with PhA in obesity, the aim of this study was to investigate their possible relationship in a group of patients with obesity stratified according to body mass index (BMI) categories.
Original paper ↗Read more →The Relationship Between Novel Inflammatory Markers and Serum 25‐Hydroxyvitamin D Among US Adults
Recent studies have investigated the correlation between serum 25‐hydroxyvitamin D (25(OH)D) and common inflammatory markers.
Original paper ↗Read more →Associations of 25 Hydroxyvitamin D and High Sensitivity C-reactive Protein Levels in Early Life
We investigated the association between longitudinal measurements of 25(OH)D and hs-CRP, respectively, from pregnancy to childhood and throughout childhood in two Danish mother: child cohorts, the COPSAC2010 and COPSAC2000.
Original paper ↗Read more →Vitamin D and Chronic Inflammation
Explains how vitamin D relates to chronic inflammation, including cytokine balance, immune regulation, metabolic links, and long-term inflammatory signalling, without making treatment claims.
Read more →Serum 25-Hydroxyvitamin D and the risk of mortality in adult patients with Sepsis: a meta-analysis
We aimed to evaluate the relationship between serum 25 (OH) D at admission and mortality risk in adult patients in a meta-analysis.
Original paper ↗Read more →The association of serum 25-hydroxyvitamin D concentrations with elevated serum ferritin levels in normal weight, overweight and obese Canadians
The objective of the present study is to examine the association of serum 25-hydroxyvitamin D [25(OH)D] with elevated SF concentrations indicative of inflammation as no earlier study has done so.
Original paper ↗Read more →Glutathione Stimulates Vitamin D Regulatory and Glucose-Metabolism Genes, Lowers Oxidative Stress and Inflammation, and Increases 25-Hydroxy-Vitamin D Levels in Blood: A Novel Approach to Treat 25-Hydroxyvitamin D Deficiency
25-Hydroxyvitamin D [25(OH)VD] deficiency/inadequacy is a major public health issue affecting more than 1 billion people worldwide.
Original paper ↗Read more →Vitamin D Genetics Beyond Serum 25(OH)D: VDR rs2228570 (FokI) Polymorphism, Inflammation, and Quality of Life in Orthopedic Patients
This study investigated the rs2228570 (FokI) variant in relation to inflammatory, hematologic, and patient-reported outcomes in orthopedic patients.
Original paper ↗Read more →Original sources
Effect of vitamin D supplementation on inflammation and nuclear factor kappa-B activity in overweight/obese adults: a randomized placebo-controlled trial
Yet, no trials have examined the effects of vitamin D supplementation on NFκB activity in-vivo in humans.
Publication details
Effect of vitamin D supplementation on inflammation and nuclear factor kappa-B activity in overweight/obese adults: a randomized placebo-controlled trial. Aya Mousa, Negar Naderpoor, Josphin Johnson, Karly Sourris, Maximilian P J de Courten, Kirsty Wilson, Robert Scragg, Magdalena Plebanski, Barbora de Courten. Scientific Reports; 2017; 7; 15154. DOI: 10.1038/s41598-017-15264-1. CC BY. This page provides an original explanatory appraisal; no source figures are reproduced.
Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial
Background: The VITAL study was a nationwide, randomized, double-blind, placebo-controlled, 2 × 2 factorial trial of vitamin D3 (2000 IU/day) and marine n-3 FAs (1 g/day) supplements.
Publication details
Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial. Yanbin Dong, Haidong Zhu, Li Chen, Ying Huang, William Christen, Nancy R Cook, Trisha Copeland, Samia Mora, Julie E Buring, I-Min Lee, Karen H Costenbader, JoAnn E Manson. Nutrients; 2022; 14; 24; 5307. DOI: 10.3390/nu14245307. CC BY. This page provides an original explanatory appraisal; no source figures are reproduced.